We Create
We help birth novel therapies to reduce patient suffering and improve health.
Learn moreHuman-enabledMachine-driven
Bespoke mini-proteins to help drug hunters deliver life-saving treatments.
Human-enabled
Machine-driven
Bespoke mini-proteins to help drug hunters deliver life-saving treatments.
Why Ordaōs
For each client, we create billions of proteins and evaluate their properties in silico to reliably and repeatedly deliver the de novo mini-proteins that drug hunters only dream of. We then prove our consistency and unparalleled efficacy by rigorously synthesizing and testing top-ranking sequences in vitro. The result is a class of mini-proteins that threaten to revolutionize the role of proteins in drug discovery.
We Extend Life
We deliver safer and more effective life-saving treaments.
Learn more
We Innovate
Our flagship solution, miniPRO™ proteins, enable drug hunters to deliver safer and more effective treatments in a fraction of the time of traditional discovery methods.
Learn more
About miniPRO Proteins
Ordaōs miniPRO™ proteins provide the power and performance of antibodies, but are configurable, more stable, and easier to scale-up and manufacture. These proteins are 20x smaller than traditional monoclonal antibodies enabling them to more easily penetrate and effectively treat disease microenvironments.
- Modular components
- Stable structure
- Configurable binding
- Non-immunogenic
Symmetry in Motion
miniPRO™ proteins make up a group of 40~160 amino acid long proteins that independently fold into single domains. The proteins act as self-contained, configurable building blocks and are engineered for the therapeutic modality of choice.
We Accelerate Discovery
The Ordaōs Design Engine generates, appraises, and ranks billions of protein sequences, hundreds of thousands of protein structures and properties to create miniPRO™, our de novo class of mini-proteins.
Learn more
About Ordaōs Design Engine
The Ordaōs Design Engine is a generative perception engine that leverages reinforcement learning and proprietary data sets to translate human-targeted product criteria into machine-designed mini-proteins. The design engine produces proteins that are more therapeutically effective, less likely to cause adverse side effects, and are easier and less expensive to develop, test, and manufacture than traditional proteins.
- Scalable, repeatable process
- Quick turnaround, highly automated
- Target and disease agnostic
- Deep learning approach beyond rational combinatorial methods
- Proprietary scoring method
- Higher probability of success
- Faster time to value
Benefits of Ordaōs System
- Scalable
- Repeatable
- Highly Automated
- Disease Agnostic
- Perceptive System
- Efficacy
- Time to Value
- IP Protected
Client Quote
"You accomplished in four-days what took us two-years to accomplish."
Dr. Philip Howe, Chair, Department of Chemistry,
Medical University of South Carolina
We Deliver
By maximizing drug candidate delivery speed, novelty, and probability of clinical success, we can provide the highest client confidence in every investigational new drug (IND) application.
What’s more, our clients see a return on their investment in weeks, rather than months or years.
See our latest news
Failure rate of drug discovery.
Drug development lifecycles.
Cost of each new drug released to market.
How Can Ordaōs Help You?
For Drug Hunters
We are a human-enabled, machine-driven drug design company that creates bespoke mini-proteins to help pharma and biotechs around the world deliver safer and more effective life-saving treatments in a fraction of the time of traditional discovery methods.
For Data Scientists
Our deep learning approach goes beyond rational combinatorial methods. We leverage a generative perception engine powered by reinforcement learning and proprietary data sets to translate human-targeted product criteria into machine-designed mini-proteins.
For Executives
By maximizing drug candidate delivery speed, novelty, and probability of clinical success, we can provide the highest client confidence in every investigational new drug (IND) application. What’s more, our clients see a return on their investment in weeks, rather than months or years.
Client Quote
"The AI-based drug design engine Ordaōs has developed is a method with game-changing potential."
Dr. Ülo Palm, Chief Medical Officer, Vaxxinity
Ordaōs in the News
We are in the news because we’re making huge strides in human-enabled, machine-driven drug design.